Toivola D - Search Results

1

Tailored Approaches in Drug Development and Diagnostics: From Molecular Design to Biological Model Systems.

Sahlgren C, Meinander A, Zhang H, Cheng F, Preis M, Xu C, Salminen TA, Toivola D, Abankwa D, Rosling A, Karaman DŞ, Salo-Ahen OMH, Österbacka R, Eriksson JE, Willför S, Petre I, Peltonen J, Leino R, Johnson M, Rosenholm J, Sandler N. Sahlgren C, et al. Among authors: toivola d. Adv Healthc Mater. 2017 Nov;6(21). doi: 10.1002/adhm.201700258. Epub 2017 Sep 11. Adv Healthc Mater. 2017. PMID: 28892296 Review.

2

Hepatocyte deformation induced by cyanobacterial toxins reflects inhibition of protein phosphatases.

Eriksson JE, Toivola D, Meriluoto JA, Karaki H, Han YG, Hartshorne D. Eriksson JE, et al. Among authors: toivola d. Biochem Biophys Res Commun. 1990 Dec 31;173(3):1347-53. doi: 10.1016/s0006-291x(05)80936-2. Biochem Biophys Res Commun. 1990. PMID: 2176489

3

Identification of protein phosphatase 2A as the primary target for microcystin-LR in rat liver homogenates.

Toivola DM, Eriksson JE, Brautigan DL. Toivola DM, et al. FEBS Lett. 1994 May 16;344(2-3):175-80. doi: 10.1016/0014-5793(94)00382-3. FEBS Lett. 1994. PMID: 8187879 Free article.

4

Protein phosphatases maintain the organization and structural interactions of hepatic keratin intermediate filaments.

Toivola DM, Goldman RD, Garrod DR, Eriksson JE. Toivola DM, et al. J Cell Sci. 1997 Jan;110 ( Pt 1):23-33. doi: 10.1242/jcs.110.1.23. J Cell Sci. 1997. PMID: 9010781

5

Protein phosphatase inhibition in normal and keratin 8/18 assembly-incompetent mouse strains supports a functional role of keratin intermediate filaments in preserving hepatocyte integrity.

Toivola DM, Omary MB, Ku NO, Peltola O, Baribault H, Eriksson JE. Toivola DM, et al. Hepatology. 1998 Jul;28(1):116-28. doi: 10.1002/hep.510280117. Hepatology. 1998. PMID: 9657104

6

Strategies to assess phosphoprotein phosphatase and protein kinase-mediated regulation of the cytoskeleton.

Eriksson JE, Toivola DM, Sahlgren C, Mikhailov A, Härmälä-Braskén AS. Eriksson JE, et al. Among authors: toivola dm. Methods Enzymol. 1998;298:542-69. doi: 10.1016/s0076-6879(98)98044-2. Methods Enzymol. 1998. PMID: 9751907 No abstract available.

7

Toxins affecting cell signalling and alteration of cytoskeletal structure.

Toivola DM, Eriksson JE. Toivola DM, et al. Toxicol In Vitro. 1999 Aug-Oct;13(4-5):521-30. doi: 10.1016/s0887-2333(99)00024-7. Toxicol In Vitro. 1999. PMID: 20654510 Free article.

8

Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer.

Mamaeva V, Rosenholm JM, Bate-Eya LT, Bergman L, Peuhu E, Duchanoy A, Fortelius LE, Landor S, Toivola DM, Lindén M, Sahlgren C. Mamaeva V, et al. Mol Ther. 2011 Aug;19(8):1538-46. doi: 10.1038/mt.2011.105. Epub 2011 May 31. Mol Ther. 2011. PMID: 21629222 Free PMC article.

9

Shape engineering vs organic modification of inorganic nanoparticles as a tool for enhancing cellular internalization.

Karaman DS, Desai D, Senthilkumar R, Johansson EM, Råtts N, Odén M, Eriksson JE, Sahlgren C, Toivola DM, Rosenholm JM. Karaman DS, et al. Among authors: toivola dm. Nanoscale Res Lett. 2012 Jul 1;7(1):358. doi: 10.1186/1556-276X-7-358. Nanoscale Res Lett. 2012. PMID: 22747910 Free PMC article.

10

Targeted modulation of cell differentiation in distinct regions of the gastrointestinal tract via oral administration of differently PEG-PEI functionalized mesoporous silica nanoparticles.

Desai D, Prabhakar N, Mamaeva V, Karaman DŞ, Lähdeniemi IA, Sahlgren C, Rosenholm JM, Toivola DM. Desai D, et al. Among authors: toivola dm. Int J Nanomedicine. 2016 Jan 18;11:299-313. doi: 10.2147/IJN.S94013. eCollection 2016. Int J Nanomedicine. 2016. PMID: 26855569 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page